BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21355626)

  • 41. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
    Festuccia C; Gravina GL; D'Alessandro AM; Muzi P; Millimaggi D; Dolo V; Ricevuto E; Vicentini C; Bologna M
    Endocr Relat Cancer; 2009 Jun; 16(2):401-13. PubMed ID: 19153211
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multi-core vesicle nanoparticles based on vesicle fusion for delivery of chemotherapic drugs.
    Yuk SH; Oh KS; Koo H; Jeon H; Kim K; Kwon IC
    Biomaterials; 2011 Nov; 32(31):7924-31. PubMed ID: 21784512
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles.
    Zhigaltsev IV; Winters G; Srinivasulu M; Crawford J; Wong M; Amankwa L; Waterhouse D; Masin D; Webb M; Harasym N; Heller L; Bally MB; Ciufolini MA; Cullis PR; Maurer N
    J Control Release; 2010 Jun; 144(3):332-40. PubMed ID: 20202473
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer.
    Hadaschik BA; ter Borg MG; Jackson J; Sowery RD; So AI; Burt HM; Gleave ME
    BJU Int; 2008 Jun; 101(11):1347-55. PubMed ID: 18384637
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer.
    Ramesh N; Ge Y; Ennist DL; Zhu M; Mina M; Ganesh S; Reddy PS; Yu DC
    Clin Cancer Res; 2006 Jan; 12(1):305-13. PubMed ID: 16397056
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin.
    Kawano H; Komaba S; Yamasaki T; Maeda M; Kimura Y; Maeda A; Kaneda Y
    Cancer Chemother Pharmacol; 2008 May; 61(6):973-8. PubMed ID: 17653716
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).
    Günther JH; Frambach M; Deinert I; Brandau S; Jocham D; Böhle A
    J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vivo studies on the availability and toxicity of antisense oligonucleotides in bladder cancer.
    Blietz CE; Thode B; Hauses M; Pries R; Meyer AJ; Doehn C; Jocham D; Kausch I
    In Vivo; 2009; 23(1):13-9. PubMed ID: 19368119
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Investigation of hydrophobically derivatized hyperbranched polyglycerol with PEGylated shell as a nanocarrier for systemic delivery of chemotherapeutics.
    Misri R; Wong NK; Shenoi RA; Lum CM; Chafeeva I; Toth K; Rustum Y; Kizhakkedathu JN; Khan MK
    Nanomedicine; 2015 Oct; 11(7):1785-95. PubMed ID: 25981338
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model.
    Wang H; Satoh M; Abe H; Sunamura M; Moriya T; Ishidoya S; Saito S; Hamada H; Arai Y
    Urology; 2006 Sep; 68(3):674-81. PubMed ID: 16979729
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer.
    Nogawa M; Yuasa T; Kimura S; Tanaka M; Kuroda J; Sato K; Yokota A; Segawa H; Toda Y; Kageyama S; Yoshiki T; Okada Y; Maekawa T
    J Clin Invest; 2005 Apr; 115(4):978-85. PubMed ID: 15761500
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination of non-viral connexin 43 gene therapy and docetaxel inhibits the growth of human prostate cancer in mice.
    Fukushima M; Hattori Y; Yoshizawa T; Maitani Y
    Int J Oncol; 2007 Jan; 30(1):225-31. PubMed ID: 17143533
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [A simple and efficient method for establishing a mouse model of orthotopic MB49 bladder cancer].
    Liang ZK; Zhang L; Hu ZM; Chen Z; Huang X; Shi XH; Tan WL; Gao JM
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Apr; 29(4):627-30. PubMed ID: 19403380
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.
    Fizazi K; Sikes CR; Kim J; Yang J; Martinez LA; Olive MC; Logothetis CJ; Navone NM
    Anticancer Res; 2004; 24(5A):2897-903. PubMed ID: 15517894
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging.
    Hadaschik BA; Black PC; Sea JC; Metwalli AR; Fazli L; Dinney CP; Gleave ME; So AI
    BJU Int; 2007 Dec; 100(6):1377-84. PubMed ID: 17850390
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intravesical interleukin-15 gene therapy in an orthotopic bladder cancer model.
    Matsumoto K; Kikuchi E; Horinaga M; Takeda T; Miyajima A; Nakagawa K; Oya M
    Hum Gene Ther; 2011 Nov; 22(11):1423-32. PubMed ID: 21554107
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy.
    Lu Z; Yeh TK; Tsai M; Au JL; Wientjes MG
    Clin Cancer Res; 2004 Nov; 10(22):7677-84. PubMed ID: 15570001
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics and tissue distribution of docetaxel by liquid chromatography-mass spectrometry: evaluation of folate receptor-targeting amphiphilic copolymer modified nanostructured lipid carrier.
    Zhao X; Zhao Y; Geng L; Li X; Wang X; Liu Z; Wang D; Bi K; Chen X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Dec; 879(31):3721-7. PubMed ID: 22035980
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy.
    Barlow L; McKiernan J; Sawczuk I; Benson M
    BJU Int; 2009 Oct; 104(8):1098-102. PubMed ID: 19389012
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Characterization of a novel transplantable orthotopic nude mouse model with xenografted human bladder transitional cell tumor (BIU-87)].
    Li C; Yan RP; Yuan GH; Feng YG; Wang JS; Gao X; Huang YS; Zhou JB; Xie SS
    Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):733-6. PubMed ID: 17366782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.